Skip to main content
AAN.com
Brief Communications
August 23, 2004

Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis

August 24, 2004 issue
63 (4) 718-720

Abstract

β-Interferon-1a (βINF-1a) is well tolerated at low dose (30 μg IM/week) in inclusion body myositis (IBM). The authors investigated the safety and tolerability of high-dose (60 μg IM/week) βINF-1a in a randomized, placebo-controlled trial in IBM. Twenty-seven of the 30 subjects enrolled completed the study. The adverse event profile was similar for the placebo and βINF-1a groups. βINF-1a, at a dose of 60 μg IM/week, is well tolerated in IBM, but no differences in muscle strength or mass were observed between the placebo and βINF-1a groups at 6 months in this pilot study.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.doc)

References

1.
Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol. 2003; 23: 199–206.
2.
Pruitt JN, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol. 1996; 39: 139–143.
3.
The Muscle Study Group. Randomized controlled trail of βINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001; 57: 1566–1570.
4.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995; 38: 705–713.
5.
Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep. 1974; 34: 1184–1186.
6.
Personius KE, Pandya S, King WM, Tawil R, McDermott MP, and FSH-DYGroup. Facioscapulohumeral muscular dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther. 1994; 74: 253–263.
7.
Forbes GB, Griggs RC, Moxley RT, Thornton CT, Tawil R. K-40 and dual energy x-ray absorptiometry of lean weight compared. Normals and patients with neuromuscular diseases. Ann NY Acad Sci. 2000; 904: 111–114.
8.
The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch Neurol. 1996; 53: 141–147.
9.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473–483.

Information & Authors

Information

Published In

Neurology®
Volume 63Number 4August 24, 2004
Pages: 718-720
PubMed: 15326251

Publication History

Received: November 4, 2003
Accepted: April 8, 2004
Published online: August 23, 2004
Published in print: August 24, 2004

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

The Muscle Study Group

Notes

Address correspondence and reprint requests to Dr. Rabi Tawil, Neuromuscular Disease Center, 601 Elmwood Avenue, Box 673, Rochester, NY 14642-8673; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Sporadic Inclusion Body Myositis at the Crossroads between Muscle Degeneration, Inflammation, and Aging, International Journal of Molecular Sciences, 25, 5, (2742), (2024).https://doi.org/10.3390/ijms25052742
    Crossref
  2. 272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands, Neuromuscular Disorders, 37, (36-51), (2024).https://doi.org/10.1016/j.nmd.2024.03.001
    Crossref
  3. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis, Neurology, 100, 13, (e1406-e1417), (2023)./doi/10.1212/WNL.0000000000206777
    Abstract
  4. Exploring challenges in the management and treatment of inclusion body myositis, Current Opinion in Rheumatology, 35, 6, (404-413), (2023).https://doi.org/10.1097/BOR.0000000000000958
    Crossref
  5. Autoimmune inflammatory myopathies, Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders, (425-460), (2023).https://doi.org/10.1016/B978-0-323-98818-6.00023-6
    Crossref
  6. Possible future avenues for myositis therapeutics: DM, IMNM and IBM, Best Practice & Research Clinical Rheumatology, 36, 2, (101762), (2022).https://doi.org/10.1016/j.berh.2022.101762
    Crossref
  7. Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis, Cells, 10, 11, (3255), (2021).https://doi.org/10.3390/cells10113255
    Crossref
  8. In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis, Current Treatment Options in Rheumatology, 7, 1, (63-81), (2021).https://doi.org/10.1007/s40674-020-00169-4
    Crossref
  9. Differential and quantitative neuroimaging characteristics of inclusion body myositis, Journal of Clinical Neuroscience, 72, (244-251), (2020).https://doi.org/10.1016/j.jocn.2019.11.029
    Crossref
  10. Inclusion body myositis: clinical features and pathogenesis, Nature Reviews Rheumatology, 15, 5, (257-272), (2019).https://doi.org/10.1038/s41584-019-0186-x
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share